Key points are not available for this paper at this time.
Although there was no significant difference in the rate of death between patients with shock who were treated with dopamine as the first-line vasopressor agent and those who were treated with norepinephrine, the use of dopamine was associated with a greater number of adverse events. (ClinicalTrials.gov number, NCT00314704.)
Building similarity graph...
Analyzing shared references across papers
Loading...
Daniel De Backer
Patrick Biston
Jacques Devriendt
New England Journal of Medicine
Université Libre de Bruxelles
Medical University of Vienna
Erasmus Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Backer et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69de755e7ed287395e558ec5 — DOI: https://doi.org/10.1056/nejmoa0907118